Kyntra Bio's Roxadustat Shows Efficacy in LR-MDS Patients, Pivotal Phase 3 Trial Planned
KYNB sits 45% above its 52-week low of $4.85 on light trading volume (0.4× avg).
Summary
Kyntra Bio announced new post-hoc data for roxadustat from its Phase 3 MATTERHORN trial, showing improved transfusion independence in lower-risk myelodysplastic syndromes (LR-MDS) patients, including those with RS- disease. In RS- patients, 48% achieved transfusion independence versus 28% for placebo. This positive clinical update supports the advancement of roxadustat, with the company finalizing the protocol for a pivotal Phase 3 trial based on FDA feedback, expected to start in H2 2026. This is a significant development for the small biotech, addressing an unmet medical need and providing a clear path forward for a key pipeline asset.
At the time of this announcement, KYNB was trading at $7.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.4M. The 52-week trading range was $4.85 to $202.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.